Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Racial differences in six major subtypes of melanoma: descriptive epidemiology

Authors: Yu Wang, Yinjun Zhao, Shuangge Ma

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Melanoma accounts for the majority of skin cancer deaths. It has over thirty different subtypes. Different races have been observed to differ in multiple aspects of melanoma.

Methods

SEER (Surveillance, Epidemiology, and End Results) data on six major subtypes, namely melanoma in situ (MIS), superficial spreading melanoma (SSM), nodular melanoma (NM), lentigo maligna melanoma (LMM), acral lentiginous melanoma malignant (ALM), and malignant melanoma NOS (NOS), were analyzed. The racial groups studied included NHW (non-Hispanic white), HW (Hispanic white), Black, and Asian/PI (Pacific Islanders). Univariate and multivariate analysis was conducted to quantify racial differences in patients’ characteristics, incidence, treatment, and survival.

Results

Significant racial differences are observed in patients’ characteristics. For all subtypes except for ALM, NHWs have the highest incidence rates, followed by HWs, while Blacks have the lowest. For ALM, HWs have the highest rate, followed by NHWs. In stratified analysis, interaction between gender and race is observed. For the first five subtypes and localized and regional NOS, the dominating majority of patients had surgery, while for distant NOS, the distribution of treatment is more scattered. Significant racial differences are observed for distant ALM and NOS. For MIS, SSM, NM, LMM, and ALM, there is no significant racial difference in survival. For NOS, significant racial differences in survival are observed for the localized and regional stages, with NHWs having the best and Blacks having the worst five-year survival rates.

Conclusions

Racial differences exist for the six major melanoma subtypes in the U.S. More data collection and analysis are needed to fully describe and interpret the differences across racial groups and across subtypes.
Literature
1.
Rebecca LS, Kimberly DM, Ahmedin J. Cancer Statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRef
2.
Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vemon SW, Cronin K, Edwards BK. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer. 2000;88(10):2398–424.CrossRefPubMed
3.
Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of California cancer registry data, 1988-93. Cancer Causes Control. 1997;8(2):246–52.CrossRefPubMed
4.
Du XL, Lin CC, Johnson NJ, Altekruse S. Effects of Individual-Level Socioeconomic Factors on Racial Disparities in Cancer Treatment and Survival: Findings from the National Longitudinal Mortality Study, 1979–2003. Cancer. 2011;117(14):3242–51.CrossRefPubMedPubMedCentral
5.
Collins KK, Fields RC, Baptiste D, Liu Y, Moley J, Jeffe DB. Racial Differences in Survival after Surgical Treatment for Melanoma. Ann Surg Oncol. 2011;18(10):2925–36.CrossRefPubMedPubMedCentral
6.
Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006;166(17):1907–14.CrossRefPubMed
7.
Reintgen DS, Mccarty KMJ, Cox E, Seigler HF. Malignant melanoma in black American and white American populations. JAMA. 1982;248(15):1856–9.CrossRefPubMed
8.
Hemmings DE, Scott JD, Tominaga GT, Wong JH. Cutaneous melanoma in a multiethnic population: is this a different disease? Arch Surg. 2004;139(9):968–72.CrossRefPubMed
9.
Newell GR, Sider JG, Bergfelt L, Kripke ML. Incidence of cutaneous melanoma in the United States by histology with special reference to the face. Cancer Res. 1988;48(17):5036–41.PubMed
10.
McGovern VJ, Shaw HM, Milton GW, Farago GA. Is malignant melanoma arising in a Hutchinson’s melanotic freckle a separate disease entity? Histopathology. 1980;4(3):235–42.CrossRefPubMed
11.
12.
13.
Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
14.
Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. Eur J Cancer Suppl. 2013;11(2):81–91.CrossRef
15.
Harvey VM, Patel H, Sandhu S, Wallington SF, Hinds G. Social Determinants of Racial and Ethnic Disparities in Cutaneous Melanoma Outcomes. Cancer Control. 2014;21(4):343–9.PubMedPubMedCentral
16.
Williams DR, Neighbors HW, Jackson JS. Racial/ethnic discrimination and health: Findings from community studies. Am J Public Health. 2003;93(2):200–8.CrossRefPubMedPubMedCentral
17.
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: Epidemiology, Risk Factors, Pathogenesis, Diagnosis and Classification. In Vivo. 2014;28(6):1005–11.PubMed
18.
Titus-Emstoff L, Perry AE, Spencer SK, Gibson JJ, Cole BF, Emstoff MS. Pigmentary characteristics and moles in relation to melanoma risk. Int J Cancer. 2005;116(1):144–9.CrossRef
19.
Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol. 2004;51(5):803–8.CrossRefPubMed
20.
21.
Nikolaus D, Hans S, Harald K, Golnaz D, Astrid F, Anja P, Thomas W. Melanoma epidemiology of Austria reveals gender-related differences. Eur J Dermatol. 2013;23(6):872–8.
22.
Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET, Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007;82(3):364–80.CrossRefPubMed
23.
Wang Y, Zhang Y, Ma S. Racial differences in nasopharyngeal carcinoma in the United States. Cancer Epidemiol. 2013;37(6):793–802.CrossRefPubMed
24.
Optenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995;274(20):1599–605.CrossRefPubMed
25.
Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163(1):49–56.CrossRefPubMed
26.
Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–57.CrossRefPubMed
27.
Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database: Applications and limitations. Med Care. 2002;40(8 Suppl):IV19–25.
28.
Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Population based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005;23(25):6054–62.CrossRefPubMed
29.
Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens Jr FL, Anton-Culver H. Survival for patients with invasive cutaneous melanoma among ethnic groups: The effects of socioeconomic status and treatment. J Clin Oncol. 2008;26(1):66–75.CrossRefPubMed
30.
Lie-Injo LE, Lopez CG, Ganesan J. Lactic Dehydrogenase variants in different racial groups in Malaysia. Hum Hered. 1973;23(5):487–91.CrossRefPubMed
31.
Morton R. Racial differences in adenocarcinoma of the prostate in North American men. Urology. 1994;44(5):637–45.CrossRefPubMed
32.
Rahman Z, Taylor SC. Malignant melanoma in African Americans. Cutis. 2001;67(5):203–406.
33.
Byrd KM, Wilson DC, Hoyler SS, Peck GL. Advanced presentation of melanoma in African Americans. J Am Acad Dermatol. 2004;50(1):21–4.CrossRefPubMed
34.
Hu S, Soza-Vento RM, Parker DF, Kirsner RS. Comparison of stage at diagnosis of melanoma among hispanic, black, and white patients in Miami-Dade County. Florida Arch Dermatol. 2006;142(6):704–8.PubMed
35.
Hutchenson AC, McGowen 4th JW, Maize Jr JC, Cook J. Multiple primary acral melanomas in African-Americans: A case series and review of the literature. Dermatol Surg. 2007;33(1):1–10.
36.
Bellows CF, Bellafsy P, Fortang IS, Beech DJ. Melanoma in African Americans: Trends in biological behavior and clinical characteristics over two decades. J Surg Oncol. 2001;78(1):10–6.CrossRefPubMed
Metadata
Title
Racial differences in six major subtypes of melanoma: descriptive epidemiology
Authors
Yu Wang
Yinjun Zhao
Shuangge Ma
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2747-6

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Study protocol

TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial

Research article

Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection

Research article

Evaluation of serum and tissue levels of VAP-1 in colorectal cancer

Research article

Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases

Research article

Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo

Research article

Association between alcohol intake and the risk of pancreatic cancer: a dose–response meta-analysis of cohort studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits